Advertisement

Tumor Biology

, Volume 35, Issue 9, pp 8639–8643 | Cite as

RETRACTED ARTICLE: Nrdp1 inhibits growth of colorectal cancer cells by nuclear retention of p27

Research Article

Abstract

The molecular mechanism underlying the proliferation of colorectal cancer (CRC) cells is not completely understood. Here, we found that the level of neuregulin receptor degradation protein-1 (Nrdp1) E3 ubiquitin ligase was significantly decreased in CRC tissues, compared with the adjacent normal tissues from human patients. Knockdown of Nrdp1 enhanced the proliferation of CRC cells, while overexpression of Nrdp1 inhibited the proliferation of CRC cells. Further analysis showed that Nrdp1 may induce degradation of its target ErbB3 to inhibit activation of both ERK/MAPK and PI3K/Akt pathways in CRC cells, which seemed to affect cell proliferation via nuclear retention of a major cell-cycle inhibitor, p27. Taken together, these findings suggest that Nrdp1-mediated ErbB3 degradation suppresses cellular growth of CRC and that Nrdp1 loss in CRC may promote tumor progression, thus highlighting Nrdp1 as a novel target for CRC therapy.

Keywords

Neuregulin receptor degradation protein-1 (Nrdp1) ErbB3 Extracellular-related kinase/mitogen-activated protein kinase (ERK/MAPK) Phosphatidylinositol 3-kinase (PI3K) Protein kinase B (Akt) Colorectal cancer 

Notes

Acknowledgments

This work was supported by the internal funding of the First Affiliated Hospital, Liaoning Medical College, China.

Conflicts of interest

None.

Reference

  1. 1.
    East JE, Dekker E. Colorectal cancer diagnosis in 2012: a new focus for CRC prevention—more serration, less inflammation. Nat Rev Gastroenterol Hepatol. 2013;10:69–70.CrossRefPubMedGoogle Scholar
  2. 2.
    Van Schaeybroeck S, Allen WL, Turkington RC, Johnston PG. Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol. 2011;8:222–32.CrossRefPubMedGoogle Scholar
  3. 3.
    Labianca R, Beretta GD, Mosconi S, Pessi MA, Milesi L. The development of clinical research in CRC. Ann Oncol. 2005;16 Suppl 4:iv37–43.PubMedGoogle Scholar
  4. 4.
    Pandurangan AK. Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mtor and Wnt pathways. Asian Pac J Cancer Prev. 2013;14:2201–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Qi J, Zhu YQ. Targeting the most upstream site of wnt signaling pathway provides a strategic advantage for therapy in colorectal cancer. Curr Drug Targets. 2008;9:548–57.CrossRefPubMedGoogle Scholar
  6. 6.
    Bienz M, Clevers H. Linking colorectal cancer to Wnt signaling. Cell. 2000;103:311–20.CrossRefPubMedGoogle Scholar
  7. 7.
    Xu Y, Pasche B. Tgf-beta signaling alterations and susceptibility to colorectal cancer. Hum Mol Genet. 2007;16(Spec No 1):R14–20.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ye Q, Cai W, Zheng Y, Evers BM, She QB. ERK And Akt signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene. 2014;33:1828–39.CrossRefPubMedGoogle Scholar
  9. 9.
    Yao YL, Shao J, Zhang C, Wu JH, Zhang QH, Wang JJ, et al. Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/erbB3/Akt and met/ErbB3/MAPK. PLoS One. 2013;8:e78086.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Yen L, Cao Z, Wu X, Ingalla ER, Baron C, Young LJ, et al. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth. Cancer Res. 2006;66:11279–86.CrossRefPubMedGoogle Scholar
  11. 11.
    von Kleist S, Chany E, Burtin P, King M, Fogh J. Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor. J Natl Cancer Inst. 1975;55:555–60.CrossRefGoogle Scholar
  12. 12.
    Xiao X, Gaffar I, Guo P, Wiersch J, Fischbach S, Peirish L, et al. M2 macrophages promote beta-cell proliferation by up-regulation of smad7. Proc Natl Acad Sci U S A. 2014;111:E1211–20.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Hang Lu
    • 1
  • Hua Li
    • 2
  • Dong Mao
    • 1
  • Zhitu Zhu
    • 2
  • Hongzhi Sun
    • 1
  1. 1.Department of Gastrointestinal Surgery, the First Affiliated HospitalLiaoning Medical CollegeJinzhouChina
  2. 2.Department of Oncology, the First Affiliated HospitalLiaoning Medical CollegeJinzhouChina

Personalised recommendations